Abstract In 2012, a 25-years-old pregnant woman presented with thromocytosis for 4 months, blood counts showed platelets 701 9 10 9 /L. Bone marrow examination disclosed a feature of hypercellular marrow in erythrocytic,granulocytic and megakaryocytic series. Cytogenetic analysis showed t(9;22)(q34;q11) in 100 % of metaphase. The percentage of BCR-ABL-positive FISH signals was 37 % in the peripheral blood. Molecular analysis showed the presence of the JAK2V617F mutation and BCR-ABL mRNA b3a2 transcript. A diagnosis of concomitant presence of essential thrombocythemia and chronic myelocytic leukemia was made. Based on this case and literatures reported before, it might be necessary to detect JAK2-V617F mutation and BCR-ABL fusion gene concomitantly in myeloproliferative neoplasms patients.
increasing WBC (14.5 9 10 9 /L) while platelet remained at the previous level (716 9 10 9 /L) on 2 days before delivery. Concomitant JAK2V617F mutation and BCR-ABL fusion gene (b3a2) of the peripheral blood were detected by allele-specific polymerase chain reaction [4] and 2-step reverse transcription PCR (RT-PCR), respectively ( Fig. 1) . Direct sequencing assay revealed heterozygous mixed-type 1894 G [ T mutation in JAK2 (Fig. 2) . Real-time quantitative PCR (RQ-PCR) of RNA showed the BCR-ABL transcript at a high level (ratio BCR-ABL/ABL: 161 %). The presence of the t (9;22) was confirmed by fluorescence in situ hybridization (FISH) using extra-signal probe (VYSIS) on peripheral blood, 37 % analyzed nuclei showed 1 yellow, 2 red and 1 green signal (Fig. 3 ). After she gave birth to a healthy girl on December 5th, BM sample was collected. BM smears revealed a hypercellular marrow with unusually increased number of platelet-producing megakaryocytes and abundant platelets, a normal myeloid: erythroid ratio (1.6:1) and normal percentage of myelocytes in differential maturation (Table 1) , the neutrophil alkaline phosphatase score was 20. Cytogenetic analysis revealed a translocation (9;22)(q34;q11) in the 100 % metaphases examined and FISH showed 67 % cells with BCR-ABL fusion signal in BM sample. According to clinical manifestation and morphology, a diagnosis of ET with concomitant JAK2V617F and BCR-ABL was made.
Discussion
MPN are classified into two major categories, CML and ph (-) MPN, such as PV, ET and PMF. MPN are often found in elderly patients and men are affected more frequently than women. Since the post-JAK2V617F era, totally 41 MPN patients have been reported with concurrent BCR-ABL junction and JAK2V617F mutation. The male and female ratio was 2:1 (24 vs 12), except for five cases without description [5] . The median age of male and female cases was 62.5 years (male: 32-71) and 68 years (female: 27-82). 11 of 12 female cases were above 52, only one case was a 27 years-old pregnant woman who was diagnosed PV and CML [3] . Few cases of concomitant ET and CML have been reported in women under the age of 30. Up to January 2013, the patient here is the second pregnant case and the youngest woman with ET and CML. Before the JAK2V617F era, PV, PMF or ET transition to CML had been reported in the literature. This pattern of disease-process was further proved by JAK2V617F mutation. The other two patterns involving JAK2V617F (?) PV, PMF or ET concurrent with CML and CML developed to JAK2V617F (?) PV, PMF or ET were reported. Although the dual genetic abnormalities were detected simultaneously in the patient here presented with ET, could we make a diagnosis of Ph (?) ET? It led the researchers to postulate the relationship between the BCR-ABL and JAK2V617F anomalies in a single patient. Which aberration happened earlier? One possibility is that the BCR-ABL is a second leukemogenic event [6] in JAK2V617F positive clone. Several reports [7] [8] [9] [10] [11] observed PV, PMF or ET with only JAK2V617F mutant clone could evolve to CML. Even in those patients who successfully treated by IM, the retrospective assessment of stored DNA samples showed that JAK2V617F mutation was already existed [12] [13] [14] . They hypothesized previously existing JAK2V617F (?) clones were masked by dominant BCR-ABL clones. Cultured colonies from a patient with both positive JAK2V617F and BCR-ABL showed the presence of JAK2V617F mutation alone or together with BCR-ABL transcripts, but in contrast, BCR-ABL transcripts were never detected alone [11] . These results also speculated JAK2V617F mutations occurs in hemopoietic stem cells as an initial step with a sub-clone acquiring an additional BCR-ABL translocation. However, other group did not found JAK2V617F clones in the previously stored samples in JAK2V617F (?) MPN and CML patients [7, 15, 16] . JAK2V617F mutation and BCR-ABL transcription were proved to exist in stem cells, respectively. Bornhäuser [8] found that the two aberrations can present in one stem cell clone (CD34?cell). Another question is in the progress of cell differentiation, whether the aberrations exist in two separated clones or in one cell clone [17] . One hypothesis is there are two independent clones each having BCR-ABL and JAK2 V617F mutation [12, [18] [19] [20] . Evidence favoring this theory is JAK2V617F diminished when BCR-ABL mRNA burden increased and reappeared once BCR-ABL mRNA levels were reduced by IM therapy [7, 19] . Another theory is JAK2V617F exist in all the myeloid cells, BCR-ABL limited to a small compartment of myeloid progenitor cells. IM induced suppression of the BCR-ABL clone but not the JAK2V617F clone. The latter remained in previous level or even higher than before. Cambier [21] and Bornhauser [8] proved that JAK2V617F mutation could be detected in granulocytic colonies and erythroid colonies, while BCR-ABL fusion existed only in granulocytic colonies but not in erythroid colonies. The case reported here should be classed into this situation because our FISH results showed t(9;22) existed in 37 % nucleiod cells. The third hypothesis is that a single stem cell clone concurrently possesses both BCR-ABL and JAK2V617F mutation. As for this mechanism, Campiotti et al. [22] observed IM therapy caused the regression of CML cells, also including those with JAK2V617F mutation. Bocchia [10] discovered evidence for the concurrent presence of BCR-ABL transcript and JAK2V617F in most of the erythroid and myeloid colonies at the time of CML diagnosis.
Together with previous reports, we would propose that clinicians need to be aware of the possibility that CML might occur on the background of JAK2V617F(?) MPN, and treatment of CML might unmask a concomitant Ph (-) MPN. It is necessary to test the concomitant presence of JAK2-V617F mutation and BCR-ABL status in MPN patients, especially in those CML patients who failed to obtain an optimal response to IM therapy or abnormal elevated blood values (Hb and/or platelets). Most recently, Inokuchi [23] reported dasatinib successfully repressed both BCR-ABL and JAK2V617F clone in the patient [24] who resisted to IM. On the contrary, Hyeoung-Joon Kim [25] reported dasatinib and nilotinib suppressed the BCR-ABL clone not the JAK2V617F clone in the past. It seems that tyrosine kinase inhibitor associated with JAK2 inhibitor could be the best choice for these dual anomalous patients.
